Nanospectra Biosciences is a medical device company headquartered in Houston, TX pioneering the patient-centric use of nanomedicine for selective photothermal ablation. The Company’s lead product platform, AuroLaseTM, maximizes treatment efficacy while minimizing side effects associated with surgery, radiation, and alternative focal therapies. It is applicable to a broad range of solid tumor indications with first human clinical indication being prostate cancer. The technology allows for the ablation of solid tumors due to the preferential and passive accumulation of proprietary gold nanoshells in the ‘leaky vasculature’ of neoplastic tissue.
Targeted thermal ablation occurs when optical energy via a low power laser is delivered directly to the tumor tissue and is transduced via the optical properties of the gold nanoshells into heat sufficient to kill the cancer cells.
The laser energy is sub-ablative in the absence of the nanoshells thus sparing healthy tissue. The fully inert, non-toxic nanoshells consist of a gold metal shell and a non-conducting silica core and serve as the exogenous absorber of the near infrared laser energy. The second of two FDA approved studies for the treatment of low to intermediate risk localized prostate cancer is presently being conducted with full enrollment in this final and pivotal study forecasted in March 2021. Regulatory submission is expected during late second quarter 2021 with FDA marketing clearance targeted for late 2021.
Radio Broadcast Feature
Begin listening at :12 in the podcast.
Get access to the important information you need from Farmers for Innovation. Using the fields below, please provide your information so that we may reach out regarding next steps and access to the FFI Data Room.